Its analysis suggests that tezepelumab is similar to Dupixent in improving symptom scores and reducing the annualised asthma exacerbation rate (AAER) in eosinophilic asthma. It matched Xolair on ...
If approved, TSLP inhibitor tezepelumab could reach the market ... Sanofi/Regeneron's IL-4/IL-13 inhibitor Dupixent (dupilumab) and AZ's own IL-5 inhibitor Fasenra (benralizumab) – which ...
Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era. But even as the billions pile up, Regeneron isn't entirely happy with ...
Dupixent (dupilumab) is a brand-name injection that’s prescribed for treating asthma. This article covers topics such as side effects, dosage, and how Dupixent works. Dupixent is available as a ...
Bristol Myers Squibb has continued its ruthless cost-cutting push, dropping plans to commercialize a rival to Dupixent despite meeting its phase 3 goals and pumping the brakes on a would-be ...
Despite Eylea's market challenges, Dupixent's strong performance and future potential in COPD, along with a robust pipeline, position Regeneron for recovery in 2025. Regeneron's solid financials ...
The CEO discussed the success of Dupixent and the remarkable achievement of over $13 billion in global sales in 2024, highlighting its commercial advantage and setting a milestone for Sanofi.
One primary reason is the strong performance and potential of Dupixent, which is expected to partially counterbalance the uncertainties surrounding Eylea. The expected growth in Dupixent’s ...
Among other topics, Hudson discussed the success of Dupixent (dupilumab), highlighting that it has reached over $13bn in global sales, which affirms its commercial advantage and sets a milestone ...
Furthermore, the successful launch of Dupixent for chronic obstructive pulmonary disease (COPD) has garnered significant coverage from top commercial and Medicare payers, indicating strong market ...
The annualized rate of moderate or severe COPD exacerbations at 52 weeks was 1.75 for tezepelumab compared with 2.11 for placebo. Tezepelumab did not significantly decrease the annualized rate of ...
According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent—including agreements with payers and pharmacy benefit managers that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results